Hot Features
Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in infectious disease in Canada. Its anti-infective portfolio includes ATI-1501, a liquid oral taste-masked reformulation of the antibiotic metronidazole to treat anae... Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in infectious disease in Canada. Its anti-infective portfolio includes ATI-1501, a liquid oral taste-masked reformulation of the antibiotic metronidazole to treat anaerobic bacterial, protozoal, and parasitic infections; ATI-1801, a novel topical formulation of paromomycin for the treatment of cutaneous leishmaniasis; and ATI-1701, a live-attenuated vaccine for the treatment of francisella tularensis. The company was incorporated in 2015 and is headquartered in Halifax, Canada. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0.015 | 0.02 | 0.015 | 90140 | 0.0182039 | CS |
| 4 | 0 | 0 | 0.015 | 0.02 | 0.015 | 106439 | 0.01580056 | CS |
| 12 | -0.005 | -25 | 0.02 | 0.02 | 0.015 | 56125 | 0.01700976 | CS |
| 26 | -0.005 | -25 | 0.02 | 0.03 | 0.015 | 47992 | 0.01897172 | CS |
| 52 | 0 | 0 | 0.015 | 0.04 | 0.01 | 97256 | 0.02814977 | CS |
| 156 | -0.02 | -57.1428571429 | 0.035 | 0.08 | 0.01 | 125789 | 0.03888861 | CS |
| 260 | -0.835 | -98.2352941176 | 0.85 | 1.14 | 0.01 | 146331 | 0.10907945 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.